Morningstar Investment Management LLC Sells 15,230 Shares of Stryker Corporation $SYK

Morningstar Investment Management LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 58.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,827 shares of the medical technology company’s stock after selling 15,230 shares during the period. Morningstar Investment Management LLC’s holdings in Stryker were worth $3,805,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of SYK. United Financial Planning Group LLC bought a new position in Stryker in the third quarter worth about $27,000. CGC Financial Services LLC bought a new position in Stryker in the fourth quarter worth about $29,000. Strive Asset Management LLC bought a new position in Stryker in the third quarter worth about $30,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker in the third quarter worth about $34,000. Finally, Copia Wealth Management raised its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after buying an additional 69 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $316.39 on Monday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a 50 day simple moving average of $325.22 and a two-hundred day simple moving average of $349.76. The company has a market capitalization of $121.29 billion, a price-to-earnings ratio of 36.62, a P/E/G ratio of 1.99 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYK. Evercore set a $355.00 price target on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company decreased their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Leerink Partners began coverage on shares of Stryker in a research note on Monday, April 13th. They set an “outperform” rating and a $410.00 target price for the company. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.